Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion type Assertion NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_head.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion description "[Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_provenance.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion evidence source_evidence_curated NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_provenance.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion SIO_000772 16763187 NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_provenance.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion wasDerivedFrom ctd_human-20130708 NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_provenance.
- NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_assertion wasGeneratedBy ECO_0000218 NP26192.RAgPVDgfDlMDqOrq3zNf3SQcrQpJRvsumjx4Mgs8ecqO8130_provenance.